3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Other hematologic neoplasm
1
Conditions
Melanoma
4
Neoplasms
3
Lymphoma, Non-Hodgkin
3
Advanced Cancer
3
Uveal Melanoma
2
Recurrence
2
Neoplasm Metastasis
2
Lymphoma, Large B-Cell, Diffuse
2
Liver Neoplasms
2
Hodgkin Disease
2
Carcinoma, Hepatocellular
2
Brain Neoplasms
2
Various Advanced Cancer
1
Tertiary Lymphoid Structures
1
Squamous Cell Carcinoma of Head and Neck
1
Spinocerebellar Degenerations
1
Sarcoma
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms by Site
1
Microsatellite Unstable Colorectal Cancer
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Glioma
1
Glioblastoma
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Interventions
Rituximab
187
Cyclophosphamide
174
Etoposide
94
Peripheral Blood Stem Cell Transplantation
90
Vincristine
89
Prednisone
80
Doxorubicin
79
Filgrastim
75
fludarabine phosphate
60
Radiotherapy
56
Mycophenolic Acid
41
Melphalan
41
Cytarabine
41
Busulfan
40
Cyclosporine
39
Methotrexate
37
Whole-Body Irradiation
36
Tacrolimus
35
Carmustine
34
Ifosfamide
28
Lenalidomide
27
Granulocyte Colony-Stimulating Factor
27
Antilymphocyte Serum
27
Gemcitabine
25
Carboplatin
25
Methylprednisolone
24
ibritumomab tiuxetan
23
Bortezomib
22
Dexamethasone
21
ibrutinib
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Lymphoma, Large B-Cell, Diffuse
×
relatlimab
×
Clear all
NCT05255601
2026-02-25
RELATIVITY-069
Bristol-Myers Squibb
Phase 1/2
Completed
5 enrolled
NCT03310619
2024-04-04
PLATFORM
Celgene
Phase 1/2
Completed
62 enrolled
41 charts